Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on April 17, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). All-stock Cullgen acquisition values target at approximately $300 million.
GYRE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- All-stock Cullgen acquisition values target at approximately $300 million
- Exchange Ratio set at 0.4753 Cullgen common shares per GYRE common share equivalent
- Certain designated holders receive Series B preferred stock convertible into five common shares
- Pre-approval issuance capped at 19.99% of GYRE common stock or voting power
- Closing and conversion depend on stockholder approval, creating execution and dilution uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GYRE THERAPEUTICS, INC. 8-K filings
Get the next GYRE 8-K as it lands
Follow GYRE for push alerts, or ask the research agent what this filing means.